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Abstract
Background: Carcinoembryonic antigen (CEA) as a marker in the follow-up after curative resection of colorectal carcinoma (CRC) is often
omitted from follow-up despite guideline recommendations. One reason is the assumption that when a normal CEA value exists before
curative resection of CRC, it will neither rise during follow-up. This study investigates this relationship.
Method: Data were derived from a study initiated to evaluate treatment regimes for rectal carcinoma (Dutch TME trial, n ¼ 1861) from
which 954 were eligible for analysis. Recurrent disease occurred in 272 of these patients (29.5%). The pre-operative CEA value was
compared to CEA values during follow-up, using threshold values of 2.5 and 5.0 ng/ml.
Results: Normal pre-operative CEAvalues were present in 63% (CEA < 5.0) and 39% (CEA < 2.5) of patients with recurrent disease. Patients
with a normal pre-operative CEA and recurrent disease had elevated CEAvalues during follow-up in 41% (CEA < 5.0), 50% (CEA < 2.5) and
in 60% with both threshold values when the last measurement was done within 3 months before recurrent disease was diagnosed.
Conclusion: A normal pre-operative CEA is common in patients with rectal carcinoma. CEA does rise due to recurrent disease in at least
50% of patients with normal pre-operative values. Serial post-operative CEA testing cannot be discarded based on a normal pre-operative
serum CEA.
 2006 Elsevier Ltd. All rights reserved.
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Carcinoembryonic antigen (CEA) as a marker in the
follow-up of colorectal carcinoma (CRC) has been sub-
jected to debate concerning it’s effectiveness to reduce can-
cer mortality. CEA is known to have the ability to detect
* Corresponding author. Tel.: þ31 (0)50 361 2301; fax: þ31 (0)50 361
1745.
E-mail addresses: i.grossmann@ziekenhuis-mst.nl (I. Grossmann),
g.h.de.bock@med.umcg.nl (G.H. de Bock), w.m.meershoek-klein_kranen
barg@lumc.nl (W.M. Meershoek-Klein Kranenbarg), c.j.h.van_de_velde
@lumc.nl (C.J.H. van de Velde), t.wiggers@chir.umcg.nl (T. Wiggers).
1 Present address: Department of Surgery, Medisch Spectrum Twente,
P.O. Box 50.000, 7500 KA Enschede, The Netherlands.0748-7983/$ - see front matter  2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejso.2006.10.035recurrent disease after curative resection of CRC at an early
stage, with approximately 5 months lead time compared to
clinical signs and several other tests. The effect on survival
is less clear, also due to the fact that only a minority of
metastasis can be treated with curative intent. Several
follow-up studies have been done with contradicting results,
successively reflected in meta-analyses and reviews1e6
that conclude there is no consistent evidence that follow-
up increases survival. The doubts about the value of CEA
in follow-up contributes to decreasing adherence to guide-
lines from oncological societies,7e10 that generally advise
to measure CEA every 3 months in the first 3 years.
Other arguments then lack of evidence may influence
leaving CEA out of follow-up as well. One of these is the
184 I. Grossmann et al. / EJSO 33 (2007) 183e187assumed relationship between serum CEA values before
and after curative surgery for colorectal carcinoma. Normal
pre-operative CEA values are often considered a reason to
omit serum CEA measurements from follow-up, because
it is widely believed it will not rise with recurrent disease
either. This belief is expressed in one regional Dutch guide-
line advising ultrasound instead of CEA measurement
when pre-operative levels are normal, and is also reported
in a recent survey.11
The threshold value of CEA is dependent on agreement;
the industrial standard is 2.0e2.5 ng/ml dependent on the
actual test. Due to frequent false-positive outcomes caused
by benign gastro-intestinal disorders and smoking, the
generally adhered threshold value in the follow-up for colo-
rectal carcinoma in the Netherlands is 5.0 ng/ml.
In literature only little evidence is available about the re-
lationship between CEA values before curative surgery and
during follow-up. Staab et al.12 were the first to describe the
relationship between serum CEA values: he observed that
in 40 patients with a normal pre-operative CEA value,
none had risen during follow-up. Three other groups,13e15
however, published data that did demonstrate CEA eleva-
tions with recurrent disease when the serum CEA value be-
fore intended curative treatment was normal. The goal of
this study is to evaluate the relationship between serum




An analysis was carried out on data derived from a study
evaluating the value of short-course radiotherapy in primary
resectable rectal carcinoma treated with standardized
surgery (Total Mesorectal Excision or TME trial) from
the Dutch ColoRectal Cancer group (DCRC-group). The
results of this study were published previously.16,17 The
registration included all actual CEA values that were mea-
sured. Serial CEA testing was required every 3 months in
the first 3 years and every 6 months in year 4 and 5, accord-
ing to the study protocol that was based on national guide-
lines. From January 1996 until December 1999, 1861
patients were included, and follow-up data are registered
until March 2006; the minimal follow-up time is therefore
more then 6 years. In this study, patients with stage 0 and
IV were excluded. Of the remaining eligible patients, the
pre-operative CEA value and at least one post-operative
CEA value were required for inclusion in this analysis.
Methods
The definition of ‘pre-operative CEA’ is the serum CEA
value measured immediately before curative resection of
the primary tumour. ‘Post-operative CEA’ is the serum
CEA value after primary surgery during follow-up. Toanalyse the rise of CEA after curative resection in relation-
ship to the pre-operative CEA value, we compared pre-
operative values to the maximum post-operative value. This
was done both for the group with and without recurrent
disease. A separate analysis was performed for the group
of patients with recurrent disease from whom the last
post-operative CEA was determined less then 3 months
before recurrent disease was diagnosed.
To analyse the response of CEA after curative surgery
(expected decrease) we compared the pre-operative CEA
to the minimum post-operative value in both the patients
with and without recurrent disease. All analyses are retro-
spectively done using two different threshold values, being




After exclusion of stage 0 and IV patients, 1701 patients
were eligible for analysis. Stage I-II-III rectal carcinoma
was diagnosed in 1665 patients, 36 patients were not
classified. Both pre- and post-operative CEA values were
available in 954 patients (56%). From these 954 patients,
recurrent disease was diagnosed in 282 patients (29.6%).
Patient demographics and tumour characteristics are de-
scribed in Table 1. The actual frequency of CEA measure-
ments was much lower then required and was never above
50% at each moment (Fig. 1).
Relationship between pre- and
post-operative CEA levels
In patients with recurrent disease (n ¼ 282), 63%
(n ¼ 179) had a normal CEA value prior to primary surgery
when apprehending a cut-off value of 5 ng/ml. Post-operative
rise of the CEA above this threshold occurred in 41%
(n ¼ 73). When a cut-off value of 2.5 ng/ml was used,
39% (n ¼ 110) had normal pre-operative CEA values.
Elevated post-operative values were then found in 50%
(n ¼ 55) (Table 2). When the last CEA was measured within
3 months before diagnosis of local recurrence or metastasis
(n ¼ 127), CEA was elevated in 59% (with a threshold of
5 ng/ml) and 61% (with a threshold of 2.5 ng/ml) (Table 3).
In patients with no recurrent disease (n ¼ 672), 77%
(n ¼ 519) had normal pre-operative CEA values when
apprehending a cut-off value of 5 ng/ml. Post-operative
rise of the CEA above this threshold during follow-up
occurred in 4% (n ¼ 19). When a cut-off value of 2.5 ng/ml
was used, 50% (n ¼ 337) had normal pre-operative CEA
values. Elevated post-operative values were then found in
13% (n ¼ 44).
In patients with recurrent disease (n ¼ 282) and an ele-
vated CEA value prior to primary surgery (n ¼ 172 at a
threshold of 2.5 ng/ml, n ¼ 103 at a threshold of 5 ng/ml),
185I. Grossmann et al. / EJSO 33 (2007) 183e187Table 1
Patient characteristics and tumour classification
Eligible patientsa (n ¼ 1701) Recurrent diseaseb (n ¼ 282) No recurrent diseaseb (n ¼ 672)
Age (years)
median (range) 66 (23e92) 64 (23e85) 64 (27e88)
Sex
Male 63% (n ¼ 1071) 67% (n ¼ 189) 61% (n ¼ 407)
Female 37% (n ¼ 630) 33% (n ¼ 93) 39% (n ¼ 265)
Tumour classificationc
Stage I 30.5% (n ¼ 519) 8.2% (n ¼ 23) 39.9% (n ¼ 268)
Stage II 29.9% (n ¼ 508) 25.5% (n ¼ 72) 31% (n ¼ 208)
Stage III 37.5% (n ¼ 638) 65.6% (n ¼ 185) 28.3% (n ¼ 190)
Unknown 2.1% (n ¼ 36) 0.7% (n ¼ 2) 0.9% (n ¼ 6)
a All patients that are eligible for inclusion in this analysis (all minus stage 0 and IV patients).
b Eligible patients with known pre- and post-operative CEA values, in total 954 patients.
c Tumour classification according to the American Joint Committee on Cancer (AJCC).CEA values were also elevated during follow-up in 79%
(n ¼ 141 at a threshold of 2.5 ng/ml) and 82% (n ¼ 81 at
a threshold of 5 ng/ml) (Table 2).
CEA values were normal after curative surgery in 98%
(n ¼ 658 at a threshold of 5 ng/ml) and 86% (n ¼ 578 at
a threshold of 2.5 ng/ml) in all patients without recurrent
disease (n ¼ 672) during follow-up. When recurrent disease
was diagnosed during follow-up (n ¼ 282), CEA values
were normal at the first measurement after curative surgery
in 81% (n ¼ 228 at a threshold of 5 ng/ml) and 66%
(n ¼ 186 at a threshold of 2.5 ng/ml).
Discussion
Summary of the results
This study suggests that a normal pre-operative CEA












3 6 9 12 15 18 21 24 27 30 33 36 42 48 54 60
Figure 1. Actual measurement of CEA during follow-up in the TME trial.
On the X-axis the moment in time CEA is recommended to be measured,
in months after primary surgery. On the Y-axis the percentage (%) of actual
measurements on that specific moment is given.recurrent disease during follow-up. A non-elevated CEA
at primary diagnosis is common (50%), as well as a rise
in CEA despite a normal pre-operative CEA (50%); this sit-
uation thus applies to a quarter of all colorectal cancer
patients.
Role of false-positive post-operative CEA levels
influencing study results
Incidental rises in CEA due to benign disease or smok-
ing are known and can be the cause of ‘falsely’ elevated
CEA levels during follow-up. This may account for a part
of the elevated post-operative CEA values in this study
because a comparison was made of the pre-operative
CEA value with the maximum CEA value during follow-
up. The proportion of these falsely elevated CEA levels
was estimated by performing the same analysis in patients
with no recurrent disease. This turned out to be limited
(4e13%). Further the pre-operative CEA was compared
with the CEA value at the time of the diagnosis of recurrent
disease, assuming at least these elevated CEA values are
due to recurrent disease. The percentage in this group
Table 2
Relationship between CEA values before and after curative surgerya in





Pre-operative value < 2.5 55 55 (50%)b





Pre-operative value < 5.0 106 73
Pre-operative value > 5.0 22 81
a The pre-operative value was compared to the highest CEA value mea-
sured during follow-up.
b The percentage of all patients with normal pre-operative CEA values
(n ¼ 110) with elevated post-operative values (n ¼ 55)
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herence with other numbers reported in literature.13e15
Value of CEA immediately after primary surgery
Not all CEA values return to normal after curative sur-
gery, especially in the group of patients that are diagnosed
with recurrent disease during follow-up, due to residual mi-
croscopic disease at time of intended curative surgery. A
persistent abnormal post-operative CEA usually indicates
synchronous metastasis or irradical resection and is appli-
cable as a marker for the effectiveness of curative surgery.
Serum CEA has a half-life of 6e60 days, and must be
expected to return to normal within several weeks.
Considerations on the relationship between pre- and
post-operative CEA levels
However it does appear that there is a relationship
between pre- and post-operative CEA levels. The thought
behind the assumption of the absence of rise in normal
pre-operative values, might not be entirely wrong. The like-
lihood CEA will rise with recurrent disease when pre-
operative values were elevated as well is higher (78%,
versus 50%) then with normal pre-operative levels. From
this observation, it might be true that looking at relative
CEA values, anticipating on an individual’s ’normal value’,
would be a more effective manner of finding abnormalities
then apprehending static cut-off values. The use of percen-
tual rise or doubling time (DT) of serum CEA values might
be effective. A strong prognostic value of this alternative has
already been demonstrated;12,15,18e20 however, no clinical
trials have been initiated up until now to study the clinical
benefit. Theoretically, by analysing the rise of CEA with
measurement at an interval of several weeks, both sensitiv-
ity and specificity can increase. A higher sensitivity is
achieved because a rise in CEA can signal recurrent disease
before crossing a static threshold, especially in patients with
low baseline values. A higher specificity is expected because
Table 3
Relationship between CEA values before curative surgery and at diagnosis





Pre-operative value < 2.5 17 27 (61%)b





Pre-operative value < 5.0 28 40
Pre-operative value > 5.0 10 49
a CEA value measured within 3 months before the diagnosis of recurrent
disease was established.
b The percentage of all patients with normal pre-operative CEA values
(n ¼ 44) with elevated post-operative values (n ¼ 27).incidental rises due to, e.g., self-limiting benign disease are
’filtered’ by repetitive measurements. Low specificity for
malignancy has been the main problem of CEA, which
has also led to the apprehension of higher threshold values
then actually are normal. Use of CEA rise, therewith antic-
ipating individual differences in CEA expression, might
solve this problem. An explanation for the variances in
CEA expression may be the production and shedding to
the circulation or intestinal lumen by different tumour
types.21e23 Immunohistochemical staining of CEA within
the cell has different cellular distribution patterns reflecting
in different serum levels. This pattern of expression and
successive differences in spilling to the circulation may be
retained in recurrent disease.
Conclusion
The majority of patients with rectal carcinoma have nor-
mal CEA values before curative surgery and half of them
will express a rise in CEA values due to recurrent disease.
This means a significant number of patients will miss an
opportunity on early detection of recurrent disease when
CEA measurements are omitted, due a false assumption.
Serial post-operative CEA testing cannot be discarded
based on a normal pre-operative serum CEA.
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